WINTON GROUP Ltd Takes Position in TransMedics Group, Inc. (NASDAQ:TMDX)

WINTON GROUP Ltd acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 17,389 shares of the company’s stock, valued at approximately $1,084,000. WINTON GROUP Ltd owned 0.05% of TransMedics Group at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of TMDX. Hager Investment Management Services LLC purchased a new stake in TransMedics Group in the 4th quarter worth approximately $33,000. Sachetta LLC purchased a new stake in shares of TransMedics Group in the fourth quarter worth $40,000. AlphaQuest LLC bought a new stake in TransMedics Group during the fourth quarter valued at $52,000. Quarry LP grew its position in TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after buying an additional 312 shares in the last quarter. Finally, National Bank of Canada FI increased its stake in TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after acquiring an additional 262 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Down 2.6 %

Shares of NASDAQ:TMDX opened at $68.58 on Friday. The stock has a market capitalization of $2.31 billion, a P/E ratio of 72.96 and a beta of 2.12. The stock’s 50-day moving average price is $69.11 and its 200-day moving average price is $88.41. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37.

Analyst Ratings Changes

TMDX has been the subject of a number of research analyst reports. Robert W. Baird dropped their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Canaccord Genuity Group reissued a “buy” rating and issued a $104.00 price target on shares of TransMedics Group in a research note on Tuesday, March 11th. JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a report on Wednesday. Finally, Oppenheimer reissued an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.